. 2016 Jan 21;3(1):2. doi: 10.3390/medicines3010002

Table 2.

Clinical Trials of Immunotherapy in Breast Cancer [16].

Immune Checkpoint Inhibitors
Study Name/NCT Identifier	Drug(s)/Novel Agent(s)	Study Phase	N	Primary Endpoint	Disease Setting
TONIC NCT02499367	Nivolumab	II	84	PFS	TNBC, ≥2^nd-line Metastatic
4147523 NCT02395627	Pembroluzimab	II	58	ORR	Postmenopausal ER+, ≥2^nd-line Metastatic
Vaccine, Small Molecule Inhibitors & Others
Study Name/Identifier	Drug(s)/Novel Agent(s)	Study Phase	N	Primary Endpoint	Disease Setting
11-202 NCT01570036	NeuVax	II	300	DFS	HER2+, Adjuvant
OSU 13117 NCT01964924	Trametinib + GSK2141795	II	41	ORR	TNBC, ≥2^nd-line Metastatic
NYU 11-00598 NCT01421017	Imiquimod	I/II	55	ORR	≥2^nd-line; + skin lesion, advance/metastatic

Abbreviations: DFS = disease free survival; N = number of patients; ORR = overall response rate; PFS = progression free survival; TNBC = triple negative breast cancer, HER2+ = human epidermal growth factor receptor positive, NCT = National Clinical Trials, OSU 13117 = unnamed novel targeted agent, NYU 11-00598 = unnamed novel targeted agent, TONIC = abbreviation for clinical trial name.